Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Current Investments: 2017-2025

  • Dr Reddys Laboratories' Cash & Current Investments fell 30.60% to $678.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.0 billion, marking a year-over-year increase of 7.36%. This contributed to the annual value of $678.0 million for FY2025, which is 30.60% down from last year.
  • According to the latest figures from Q1 2025, Dr Reddys Laboratories' Cash & Current Investments is $678.0 million, which was down 30.60% from $977.0 million recorded in Q1 2024.
  • In the past 5 years, Dr Reddys Laboratories' Cash & Current Investments registered a high of $977.0 million during Q1 2024, and its lowest value of $473.0 million during Q1 2021.
  • Over the past 3 years, Dr Reddys Laboratories' median Cash & Current Investments value was $752.0 million (recorded in 2023), while the average stood at $802.3 million.
  • As far as peak fluctuations go, Dr Reddys Laboratories' Cash & Current Investments spiked by 38.71% in 2021, and later tumbled by 30.60% in 2025.
  • Quarterly analysis of 5 years shows Dr Reddys Laboratories' Cash & Current Investments stood at $473.0 million in 2021, then climbed by 23.68% to $585.0 million in 2022, then climbed by 28.55% to $752.0 million in 2023, then increased by 29.92% to $977.0 million in 2024, then slumped by 30.60% to $678.0 million in 2025.
  • Its last three reported values are $678.0 million in Q1 2025, $977.0 million for Q1 2024, and $752.0 million during Q1 2023.